WO2009007746A3 - Treatment of sensorineural hearing loss - Google Patents

Treatment of sensorineural hearing loss Download PDF

Info

Publication number
WO2009007746A3
WO2009007746A3 PCT/GB2008/050542 GB2008050542W WO2009007746A3 WO 2009007746 A3 WO2009007746 A3 WO 2009007746A3 GB 2008050542 W GB2008050542 W GB 2008050542W WO 2009007746 A3 WO2009007746 A3 WO 2009007746A3
Authority
WO
WIPO (PCT)
Prior art keywords
agents
present disclosure
treatment
hearing loss
sensorineural hearing
Prior art date
Application number
PCT/GB2008/050542
Other languages
French (fr)
Other versions
WO2009007746A2 (en
Inventor
Carlos Marcelo Nicolas Rivolta
Original Assignee
Univ Sheffield
Carlos Marcelo Nicolas Rivolta
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Sheffield, Carlos Marcelo Nicolas Rivolta filed Critical Univ Sheffield
Publication of WO2009007746A2 publication Critical patent/WO2009007746A2/en
Publication of WO2009007746A3 publication Critical patent/WO2009007746A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4833—Thrombin (3.4.21.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/18—Internal ear or nose parts, e.g. ear-drums
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/484—Plasmin (3.4.21.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Cardiology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present disclosure relates to agents which act to stimulate auditory neuron differentiation. The present disclosure also relates to the stimulation of neurite production of existing neurons using the agents. Included in the present disclosure are methods of treating neurosensory deafness comprising administering agents which are capable of stimulating auditory neuronal differentiation and/or neurite production. Exemplary agents include, for example, Protease Activated Receptor (PAR) agonists.
PCT/GB2008/050542 2007-07-06 2008-07-07 Treatment of sensorineural hearing loss WO2009007746A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0713139.4 2007-07-06
GB0713139A GB2450747A (en) 2007-07-06 2007-07-06 Treatment of sensorineural hearing loss

Publications (2)

Publication Number Publication Date
WO2009007746A2 WO2009007746A2 (en) 2009-01-15
WO2009007746A3 true WO2009007746A3 (en) 2009-03-05

Family

ID=38440509

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2008/050542 WO2009007746A2 (en) 2007-07-06 2008-07-07 Treatment of sensorineural hearing loss

Country Status (2)

Country Link
GB (1) GB2450747A (en)
WO (1) WO2009007746A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102016110642A1 (en) 2016-06-09 2017-12-14 Nordmark Holding Gmbh Use of ancrod for the prevention and / or treatment of ischemia
GB201615714D0 (en) * 2016-09-15 2016-11-02 Univ Of Sheffield The Otic progenitor identification and isolation

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2231263A (en) * 1989-05-08 1990-11-14 Shigemi Fujisaki Use of neutral protease as activator for damaged neurocytes
EP0592903A2 (en) * 1992-10-14 1994-04-20 Basf Corporation Use of ancrod for the preparation of drugs for the treatment of restenosis
WO2000015243A1 (en) * 1998-09-15 2000-03-23 The University Of Melbourne A method of treatment and agents useful for same
WO2002004008A2 (en) * 2000-07-12 2002-01-17 The Board Of Regents, The University Of Texas System Methods of therapy with thrombin derived peptides
EP1258251A1 (en) * 2000-02-24 2002-11-20 Fuso Pharmaceutical Industries Ltd. Compositions for preventing and treating digestive diseases
US20030175263A1 (en) * 2002-03-13 2003-09-18 Trese Michael T. Modification of vitreal matrix metalloproteinase activity
WO2003079978A2 (en) * 2002-03-18 2003-10-02 Beth Israel Deaconess Medical Center Protease activity of thrombin inhibits angiogenesis
EP1790354A2 (en) * 2001-09-06 2007-05-30 Omnio AB Use of plasminogen for promoting healing of tympanic membrane perforation

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010041418A (en) * 1998-02-27 2001-05-15 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 Protease-activated receptor 4 and uses thereof
GB9908513D0 (en) * 1999-04-15 1999-06-09 Rolls Royce Plc Molecular cloning of a new DNA sequence for protease activated receptor 2
WO2001094411A1 (en) * 2000-06-05 2001-12-13 The Regents Of The University Of California Peptides modulating protease activated receptors and methods of using same
WO2004073504A2 (en) * 2003-02-20 2004-09-02 Proteon Therapeutics, Llc Methods for the treatment and prevention of diseases of biological conduits
US20060104944A1 (en) * 2004-11-18 2006-05-18 Mousa Shaker A Activators and inhibitors of protease activated receptor2 (PAR2) and methods of use
EP1845104A4 (en) * 2004-12-28 2009-08-05 Kowa Co Par-2 agonist
WO2007049096A1 (en) * 2005-10-25 2007-05-03 Inserm (Institut National De La Sante Et De La Recherche Medicale) A method of expansion of endothelial progenitor cells

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2231263A (en) * 1989-05-08 1990-11-14 Shigemi Fujisaki Use of neutral protease as activator for damaged neurocytes
EP0592903A2 (en) * 1992-10-14 1994-04-20 Basf Corporation Use of ancrod for the preparation of drugs for the treatment of restenosis
WO2000015243A1 (en) * 1998-09-15 2000-03-23 The University Of Melbourne A method of treatment and agents useful for same
EP1258251A1 (en) * 2000-02-24 2002-11-20 Fuso Pharmaceutical Industries Ltd. Compositions for preventing and treating digestive diseases
WO2002004008A2 (en) * 2000-07-12 2002-01-17 The Board Of Regents, The University Of Texas System Methods of therapy with thrombin derived peptides
EP1790354A2 (en) * 2001-09-06 2007-05-30 Omnio AB Use of plasminogen for promoting healing of tympanic membrane perforation
US20030175263A1 (en) * 2002-03-13 2003-09-18 Trese Michael T. Modification of vitreal matrix metalloproteinase activity
WO2003079978A2 (en) * 2002-03-18 2003-10-02 Beth Israel Deaconess Medical Center Protease activity of thrombin inhibits angiogenesis

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MORA RENZO ET AL: "Restoration of hearing loss with tissue plasminogen activator. Case report.", ANNALS OF OTOLOGY RHINOLOGY AND LARYNGOLOGY, vol. 112, no. 8, August 2003 (2003-08-01), pages 671 - 674, XP009109636, ISSN: 0003-4894 *

Also Published As

Publication number Publication date
GB2450747A (en) 2009-01-07
WO2009007746A2 (en) 2009-01-15
GB0713139D0 (en) 2007-08-15

Similar Documents

Publication Publication Date Title
WO2009105690A3 (en) Devices and methods for delivering polynucleotides into retinal cells of the macula and fovea
WO2006083675A3 (en) A stimulating device
WO2010002936A3 (en) Systems, methods and devices for paired plasticity
WO2014172693A3 (en) Nasal stimulation devices and methods
GB2463833A (en) Methods and compositions for the treatment of neurological disorders
WO2007134136A3 (en) Neurogenesis by modulating angiotensin
WO2007011611A3 (en) Deep brain neural prosthetic system
EP2038004A4 (en) Treatment of neurological disorders via electrical stimulation, and methods related thereto
WO2015130707A3 (en) Polymer formulations for nasolacrimal stimulation
TW200633709A (en) Aminopyrazine analogs for treating glaucoma and other rho kinase-mediated diseases and conditions
WO2009037689A3 (en) Electrical stimulation in the middle ear for treatment of hearing related disorders
WO2011156286A3 (en) Stimulation therapy for bladder dysfunction
WO2009044271A3 (en) Systems and methods for treatment of medical conditions related to the central nervous system and for enhancing cognitive functions
WO2009038720A3 (en) Method and apparatus for applying light therapy
WO2008097861A3 (en) MODULATION OF NEUROGENESIS WITH BIGUANIDES AND GSK3-ß AGENTS
WO2008106605A3 (en) Method for stimulating retinal response using photoactive devices
WO2007022470A3 (en) Methods and compositions for treating neurological disease
WO2008029276A8 (en) Compositions and methods for the treatment of ophthalmic disease
WO2020112980A3 (en) Head worn apparatuses for vision therapy
MY168084A (en) Methods for treating and/or reversing neurodegenerative diseases and/or disorders
GB0512038D0 (en) Therapeutic and cosmetic uses of electromagnetic radiation
MX2019009190A (en) Use of gaboxadol in the treatment of tinnitus.
WO2006014159A3 (en) Methods of using regenerative cells in the treatment of musculoskeletal disorders
MX2017004133A (en) Deep brain stimulation electrode, device and method.
WO2010018996A3 (en) Human neural stem cell, and pharmaceutical composition for the treatment of central or peripheral nervous system disorders and injuries using same

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08776177

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08776177

Country of ref document: EP

Kind code of ref document: A2